This data are consistent with the known role of VHL as a gatekeeper tumour suppressor gene and suggests that CDKN2A loss and MYC activation are events involved in the progression of a subset of ccRCC tumours. The gene discussed is CDKN2A; the disease is nonpapillary renal cell carcinoma.